These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32852698)

  • 1. GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression.
    Qiu M; Ding LL; Zhang M; Lin JH; Wei XB; Huang H
    Diabetes Ther; 2020 Oct; 11(10):2429-2440. PubMed ID: 32852698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes.
    Lee MMY; Ghouri N; McGuire DK; Rutter MK; Sattar N
    Diabetes Care; 2021 May; 44(5):1236-1241. PubMed ID: 33707305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
    Cotter G; Davison BA; Edwards C; Senger S; Teerlink JR; Zannad F; Nielsen OW; Metra M; Mebazaa A; Chioncel O; Greenberg BH; Maggioni AP; Ertl G; Sato N; Cohen-Solal A
    Am Heart J; 2021 Oct; 240():73-80. PubMed ID: 34107289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M; Maisnam I; Mukhopadhyay S
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):739-746. PubMed ID: 36696050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2022 Aug; 45(8):1900-1906. PubMed ID: 35775451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY; Liu SY; Yin DG
    Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review.
    Scheen AJ
    Diabetes Metab; 2024 Mar; 50(2):101508. PubMed ID: 38158077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
    Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
    Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
    Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.
    Lavalle-Cobo A; Masson W; Lobo M; Masson G; Molinero G
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):605-612. PubMed ID: 34705249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures.
    Wang DH; Mo YX; Tan X; Xie JY; Wang H; Wen F
    Acta Diabetol; 2024 May; ():. PubMed ID: 38714558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2020; 14(4):715-722. PubMed ID: 32470852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
    Qiu M; Ding L; Zhou H
    Medicine (Baltimore); 2021 Mar; 100(10):e25121. PubMed ID: 33725910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.
    Qiu M; Ding LL; Zhou HR
    Am J Cardiovasc Drugs; 2022 Jan; 22(1):69-81. PubMed ID: 34231123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.
    Rodriguez-Valadez JM; Tahsin M; Masharani U; Park M; Hunink MGM; Yeboah J; Li L; Weber E; Berkalieva A; Avezaat L; Max W; Fleischmann KE; Ferket BS
    J Am Heart Assoc; 2024 Feb; 13(4):e032463. PubMed ID: 38362889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.